MOMTAZEE JAMES C 4

What Happened

• James C. Momtazee, a non-employee director of Roivant Sciences Ltd. (ROIV), was granted 469 common shares that were fully vested on 2026-04-17. The award shows an acquisition of 469 shares at $0.00.
• To satisfy tax withholding, the issuer net-settled 94 of those shares at $29.83 per share, resulting in a disposition/value of approximately $2,804. This is an award (A) with a tax-withholding net settlement (F), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-17 (reported on Form 4 filed 2026-04-21).
• Award: 469 shares granted/vested (code A) at $0.00 reported price.
• Tax withholding/net settlement: 94 shares withheld (code F) at $29.83 per share ≈ $2,804.
• Shares owned after transaction: not specified in the provided details.
• Footnotes: F1 notes the shares were granted under the Non-Employee Director Compensation Plan and were fully vested on the grant date. F2 explains the 94-share disposition reflects the issuer’s net settlement of shares to satisfy tax withholding.
• Filing timeliness: Form 4 was filed on 2026-04-21 for a 2026-04-17 transaction; this appears to be timely (filed within the SEC’s two-business-day window).

Context

• This was not a buy or sell signaling market sentiment; it was a routine director compensation award with a standard net-share settlement to cover tax obligations. For retail investors, purchases by insiders can be more directly informative than routine compensation-related transactions like this one.